(Q45880221)

17 December 2017

title

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy (English)

1 reference

17 December 2017

1 reference

1 reference

8

1 reference

17 December 2017

Pier Mannuccio Mannucci

7

object named as

Pier M Mannucci

1 reference

17 December 2017

Marta Spreafico

1

1 reference

17 December 2017

Corrado Lodigiani

2

1 reference

17 December 2017

Y van Leeuwen

3

1 reference

17 December 2017

Denise Pizzotti

4

1 reference

17 December 2017

Lidia L Rota

5

1 reference

17 December 2017

Fr Rosendaal

6

1 reference

17 December 2017

publication date

1 September 2008

1 reference

17 December 2017

published in

Pharmacogenomics

1 reference

17 December 2017

volume

9

1 reference

17 December 2017

issue

9

1 reference

17 December 2017

page(s)

1237-1250

1 reference

17 December 2017

Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenetics of warfarin elimination and its clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenetics of acenocoumarol pharmacodynamics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Acenocoumarol stabilization is delayed in CYP2C93 carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Differential effects of 2C9*3 and 2C9*2 variants of cytochrome P-450 CYP2C9 on sensitivity to acenocoumarol

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Warfarin and acenocoumarol dose requirements according to CYP2C9 genotyping in North-Italian patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Identification of the gene for vitamin K epoxide reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Common VKORC1 and GGCX polymorphisms associated with warfarin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Evaluation of genetic factors for warfarin dose prediction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

The genetic interaction between VKORC1 c1173t and calumenin a29809g modulates the anticoagulant response of acenocoumarol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Genetic determinants of response to warfarin during initial anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A simple salting out procedure for extracting DNA from human nucleated cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Association of warfarin dose with genes involved in its action and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Genetic-based dosing in orthopedic patients beginning warfarin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14622416.9.9.1237

10.2217/14622416.9.9.1237

21 January 2018

Identifiers

DOI

1 reference

17 December 2017

1 reference

17 December 2017